Area of research
Oncology · Epidemiology
Research interest
Research interests include Medicine, Internal medicine, Durvalumab, Adverse effect, Colorectal cancer, and Rash.
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer